New interest has appeared on 5F-ADB, a synthetic opioid falling under the broader category of designer compounds. Limited information currently is available regarding its precise pharmacological effects, but initial reports suggest it acts as a powerful activator at serotonin receptors, potentially producing effects like those of established copyri